Glucocorticoid Enhances Transforming Growth Factor-β Effects on Extracellular Matrix Protein Expression in Human Placental Mesenchymal Cells

Biology of Reproduction

Volumn 70, Issue 5, 2004, Pages 1246-1252

  Lee, Men Jean ^a   Ma, Yuehong ^a   LaChapelle, Linda ^a   Kadner, Susan S ^a   Guller, Seth ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cortisol; Glucocorticoid receptor; Placenta; Pregnancy

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; DEXAMETHASONE; FIBRONECTIN; GLUCOCORTICOID; LAMININ; ONCOFETAL ANTIGEN; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL HYPOXIA; CELL ISOLATION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE PROTEIN COMPLEX; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MESENCHYME CELL; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PLACENTA; PLACENTA VILLUS; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM;

BLOTTING, NORTHERN; CELL HYPOXIA; CELLS, CULTURED; COMPUTER SYSTEMS; DEXAMETHASONE; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBRONECTINS; GLUCOCORTICOIDS; HUMANS; MESODERM; PLACENTA; POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA; TROPHOBLASTS;

MAMMALIA;

EID: 1942540785     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod.103.021956     Document Type: Article

References (53)

1. Benirschke K, Kaufmann P. Placental types. In: Pathology of the Human Placenta, 2nd ed. New York: Springer-Verlag; 1990:1-12.
2. Amenta PS, Gay S, Vaheri A, Martinez-Hernandez A. The extracellular matrix is an integrated unit: ultrastructural localization of collagen types I, III, IV, V, VI, fibronectin, and laminin in human term placenta. Coll Relat Res 1986; 6:125-152.
3. Yamada T, Isemura M, Yamaguchi Y, Munakata H, Hayashi N, Kyogoku M. Immunohistochemical localization of fibronectin in the human placentas at their different stages of maturation. Histochemistry 1987; 86:579-584.
4. Chen CP, Aplin JD. Placental extracellular matrix: gene expression, deposition by placental fibroblasts and the effect of oxygen. Placenta 2003; 24:316-325.
5. Damsky CH, Fitzgerald ML, Fisher SJ. Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo. J Clin Invest 1992; 89:210-222.
6. 1. Biol Reprod 1999; 60: 828-838.
7. Genbacev O, McMaster MT, Fisher SJ. A repertoire of cell cycle regulators whose expression is coordinated with human cytotrophoblast differentiation. Am J Pathol 2000; 157:1337-1351.
8. Ma Y, Lockwood CJ, Bunim AL, Giussani DA, Nathanielsz PW, Guller S. Cell-type specific regulation of fetal fibronectin (FFN) expression in amnion: conservation of glucocorticoid responsiveness in human and nonhuman primates. Biol Reprod 2000; 62:1812-1817.
9. Macara L, Kingdom JC, Kaufmann P, Kohnen G, Hair J, More IA, Lyall F, Greer IA. Structural analysis of placental terminal villi from growth-restricted pregnancies with abnormal umbilical artery Doppler waveforms. Placenta 1996; 17:37-48.
10. Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated pathologic features. Am J Obstet Gynecol 1995; 173:1049-1057.
11. Heldin CH, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390:465-471.
12. Graham CH, Lysiak JJ, McCrae KR, Lala PK. Localization of transforming growth factor-β at the human fetal-maternal interface: role in trophoblast growth and differentiation. Biol Reprod 1992; 46:561-572.
13. Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, Post M, Lye SJ. Inhibition of TGF-β3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest 1999; 103: 1641-1650.
14. Simpson H, Robson SC, Bulmer JN, Barber A, Lyall F. Transforming growth factor β expression in human placenta and placental bed during early pregnancy. Placenta 2002; 23:44-58.
15. Mitchell EJ, O'Connor-McCourt MD. A transforming growth factor beta (TGF-β) receptor from human placenta exhibits a greater affinity for TGF-β than for TGF-β1. Biochemistry 1991; 30:4350-4356.
16. Mitchell EJ, Fitz-Gibbon L, O'Connor-McCourt MD. Subtypes of betaglycan and of type I and type II transforming growth factor-beta (TGF-β) receptors with different affinities for TGF-β1 and TGF-β2 are exhibited by human placental trophoblast cells. J Cell Physiol 1992; 150:334-343.
17. Ando N, Hirahara F, Fukushima J, Kawamoto S, Okuda K, Funabashi T, Gorai I, Minaguchi H. Differential gene expression of TGF-β isoforms and TGF-β receptors during the first trimester of pregnancy at the human maternal-fetal interface. Am J Reprod Immunol 1998; 40: 48-56.
18. Roberts CJ, Birkenmeier TM, McQuillan JJ, Akiyama SK, Yamada SS, Chen WT, Yamada KM, McDonald JA. Transforming growth factor β stimulates the expression of fibronectin and of both subunits of the human fibronectin receptor by cultured human lung fibroblasts. J Biol Chem 1988; 263:4586-4592.
19. Heino J, Ignotz RA, Hemler ME, Crouse C, Massague J. Regulation of cell adhesion receptors by transforming growth factor-β. Concomitant regulation of integrins that share a common β1 subunit. J Biol Chem 1989; 264:380-388.
20. Ignotz RA, Massague J. Cell adhesion protein receptors as targets for transforming growth factor-β action. Cell 1987; 51:189-197.
21. Matsuura H, Hakomori SI. The oncofetal domain of fibronectin defined by the monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those normal adult tissues and plasma. Proc Natl Acad Sci U S A 1985; 82:6517-6521.
22. Feinberg RF, Kliman HJ, Lockwood CJ. Is oncofetal fibronectin a trophoblast glue for implantation? Am J Pathol 1991; 138:537-543.
23. Feinberg RF, Kliman HJ, Wang CL. Transforming growth factor-beta stimulates trophoblast oncofetal fibronectin synthesis in vitro: implications for trophoblast implantation in vivo. J Clin Endocrinol Metab 1994; 78:1241-1248.
24. Guller S, Wozniak R, Lockwood CJ. Antagonism of transforming growth factor-β-mediated effects on extracellular matrix protein expression in the human placenta by glucocorticoids. J Clin Endocrinol Metab 1995; 80:3273-3278.
25. Yoon DY, Ma Y, Krikun G, Lockwood CJ, LaChapelle L, Guller S. Glucocorticoid effects in the human placenta: evidence that dexamethasone-mediated inhibition of fibronectin expression in cytotrophoblasts involves a protein intermediate. J Clin Endocrinol Metab 1998; 83:632-637.
26. Guller S, Markiewicz L, Wozniak R, Burnham JM, Wang E-Y, Kaplan P, and Lockwood CJ. Developmental regulation of glucocorticoid-mediated effects on extracellular matrix protein expression in the human placenta. Endocrinology 1994; 134:2064-2071.
27. Dorr HG, Heller A, Versmold HT, Sippel WG, Herrmann M, Bidlingmaier F, Knorr D. Longitudinal study of progestins, mineralocorticoids, and glucocorticoids throughout human pregnancy. J Clin Endocrinol Metab 1989; 68:863-868.
28. Brooks AN, Challis JRG. Regulation of the hypothalmic-pituitary-adrenal axis in birth. Can J Physiol Pharmacol 1988; 66:1106-1112.
29. Fant ME, Nanu L. Human placental endothelin: expression of endothelin-1 mRNA by human placental fibroblasts in culture. Mol Cell Endocrinol 1995; 109:119-123.
30. Guller S, LaCroix N, Krikun G, Wozniak R, Markiewicz L, Wang E-Y, Kaplan P, and Lockwood CJ. Steroid regulation of oncofetal fibronectin expression in human cytotrophoblasts. J Steroid Biochem Molec Biol 1993; 46:1-10.
31. Kliman HJ, Nestler JE, Sermasi E, Sanger JM, Strauss III JF. Purification, characterization, and in vitro differentiation of cytotrophoblasts from human term placentae. Endocrinology 1986; 118:1567-1582.
32. Douglas GC, King BF. Isolation of pure villous cytotrophoblast from human term placenta using immunomagnetic microspheres. J Immunol Methods 1989; 119:259-268.
33. Guller S, Wozniak R, Krikun G, Burnham JM, Kaplan P, Lockwood CJ. Glucocorticoid suppression of human placental fibronectin expression: implications in uterine-placental adherence. Endocrinology 1993; 133:1139-1146.
34. Ma Y, Ryu JS, Dulay A, Segal M, Guller S. Regulation of plasminogen activator inhibitor (PAI)-1 expression in a human trophoblast cell line by glucocorticoid and transforming growth factor (TGF)-β. Placenta 2002; 23:727-734.
35. Esterman A, Finlay TH, Dancis J. The effect of hypoxia on term trophoblast: hormone synthesis and release. Placenta 1996; 17:217-222.
36. Berg JT, Breen EC, Fu Z, Mathieu-Costello O, West JB. Alveolar hypoxia increases gene expression of extracellular matrix proteins and platelet-derived growth factor-B in lung parenchyma. Am J Respir Crit Care Med 1998; 158:1920-1928.
37. Kim SB, Kang SA, Park JS, Lee JS, Hong CD. Effects of hypoxia on the extracellular matrix production of cultured rat mesangial cells. Nephron 1996; 72:275-280.
38. Agocha A, Lee HW, Eghbali-Webb M. Hypoxia regulates basal and induced DNA synthesis and collagen type I production in human cardiac fibroblasts: effects of transforming growth factor-β1, thyroid hormone, angiotensin II and basic fibroblast growth factor. J Mol Cell Cardiol 1997; 29:2233-2244.
39. Song CZ, Tian X &, Gelehrter TD. Glucocorticoid receptor inhibits transforming growth factor-β signaling by directly targeting the transcriptional activation function of Smad3. Proc Natl Acad Sci U S A 1999; 96:11776-11781.
40. Falanga V, Qian SW, Danielpour D, Katz MH, Roberts AB, Sporn MB. Hypoxia upregulates the synthesis of TGF-β1 by human dermal fibroblasts. J Invest Dermatol 1991; 97:634-637.
41. Khaliq A, Patel B, Jarvis-Evans J, Moriarty P, McLeod D, Boulton M. Oxygen modulates production of bFGF and TGF-β by retinal cells in vitro. Exp Eye Res 1995; 60:415-423.
42. Orphanides C, Fine LG, Norman JT. Hypoxia stimulates proximal tubular cell matrix production via a TGF-β1-independent mechanism. Kidney Int 1997; 52:637-647.
43. Frank S, Madlener M, Werner S. Transforming growth factors β1, β2, and β3 and their receptors are differentially regulated during normal and impaired wound healing. J Biol Chem 1996; 271:10188-10193.
44. Chang DJ, Ji C, Kim KK, Casinghino S, McCarthy TL, Centrella M. Reduction in transforming growth factor β receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J Biol Chem 1998; 273:4892-4896.
45. Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care 1998; 11:277-285.
46. Salafia CM, Pezzullo JC, Minior VK, Divon MY. Placental pathology of absent and reversed end-diastolic flow in growth-restricted fetuses. Obstet Gynecol 1997; 90:830-836.
47. Abramowicz JS, Warsof SL, Arrington L, Levy DL. Doppler analysis of the umbilical artery. The importance of choosing the placental end of the cord. J Ultrasound Med 1989; 8:219-221.
48. Lee MJ, Charafeddine L, Woods JR, Del Priore. Birthweight determines survival in premature severely growth-retarded newborns. Am J Obstet Gynecol 1995; 172:367.
49. Heckmann M, Wudy SA, Haack D, Pohlandt F. Reference range for serum cortisol in well preterm infants. Arch Dis Child Fetal Neonatal Ed 1999; 81:F171-F174.
50. Parker CR Jr, Buchina ES, Barefoot TK. Abnormal adrenal steroidogenesis in growth-retarded newborn infants. Pediatr Res 1994; 35: 633-636.
51. Seckl JR. Glucocorticoids, feto-placental 11β-hydroxysteroid dehydrogenase type 2, and the early life origins of adult disease. Steroids 1997; 62:89-94.
52. Shams M, Kilby MD, Somerset DA, Howie AJ, Gupta A, Wood PJ, Afnan M, Stewart PM. 11β-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction. Hum Reprod 1998; 13:799-804.
53. Ghidini A, Pezzullo JC, Sylvestre G, Lembet A, Salafia CM. Ante-natal corticosteroids and placental histology in preterm birth. Placenta 2001; 22:412-417.